Tags

Type your tag names separated by a space and hit enter

Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins.
Metabolism. 1992 May; 41(5):487-93.M

Abstract

We have previously reported decreased production rates of the major apolipoprotein B (apoB)-containing lipoproteins, very-low-density lipoproteins (VLDL), and low-density lipoproteins (LDL) in patients with combined hyperlipidemia (CHL) during treatment with lovastatin. In the present study, we determined the effects of lovastatin therapy on VLDL triglyceride (TG) metabolism. Plasma VLDL turnover was determined in six CHL patients, before and during lovastatin therapy. 3H-triglyceride-glycerol-specific activity data derived from injection of 3H-glycerol were analyzed by compartmental modeling. The effects of lovastatin on VLDL TG metabolism were compared with those previously determined on VLDL apoB metabolism in these subjects. Lovastatin therapy was associated with decreased concentrations of VLDL TG in five of six patients and decreased VLDL apoB concentrations in all six. VLDL TG production rates (PR) decreased in five patients, with the mean for the group decreasing from 14.1 +/- 7.1 to 10.3 +/- 4.0 mg/kg/h (P less than .05). VLDL apoB PR also decreased in five patients, with the mean decreasing from 21.8 +/- 20.3 to 12.2 +/- 9.0 mg/kg/d (P = .11). Changes in VLDL TG concentrations during lovastatin treatment were correlated with changes in VLDL apoB concentrations (r = .74, P = .09) and in VLDL TG PR (r = .91, P = .01). Changes in VLDL TG PR were also related to changes in VLDL apoB PR (r = .62, P = NS). There were no consistent changes in the fractional catabolic rates of either VLDL TG or VLDL apoB during lovastatin therapy.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

1588827

Citation

Arad, Y, et al. "Effects of Lovastatin Therapy On Very-low-density Lipoprotein Triglyceride Metabolism in Subjects With Combined Hyperlipidemia: Evidence for Reduced Assembly and Secretion of Triglyceride-rich Lipoproteins." Metabolism: Clinical and Experimental, vol. 41, no. 5, 1992, pp. 487-93.
Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 1992;41(5):487-93.
Arad, Y., Ramakrishnan, R., & Ginsberg, H. N. (1992). Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism: Clinical and Experimental, 41(5), 487-93.
Arad Y, Ramakrishnan R, Ginsberg HN. Effects of Lovastatin Therapy On Very-low-density Lipoprotein Triglyceride Metabolism in Subjects With Combined Hyperlipidemia: Evidence for Reduced Assembly and Secretion of Triglyceride-rich Lipoproteins. Metabolism. 1992;41(5):487-93. PubMed PMID: 1588827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. AU - Arad,Y, AU - Ramakrishnan,R, AU - Ginsberg,H N, PY - 1992/5/1/pubmed PY - 1992/5/1/medline PY - 1992/5/1/entrez SP - 487 EP - 93 JF - Metabolism: clinical and experimental JO - Metabolism VL - 41 IS - 5 N2 - We have previously reported decreased production rates of the major apolipoprotein B (apoB)-containing lipoproteins, very-low-density lipoproteins (VLDL), and low-density lipoproteins (LDL) in patients with combined hyperlipidemia (CHL) during treatment with lovastatin. In the present study, we determined the effects of lovastatin therapy on VLDL triglyceride (TG) metabolism. Plasma VLDL turnover was determined in six CHL patients, before and during lovastatin therapy. 3H-triglyceride-glycerol-specific activity data derived from injection of 3H-glycerol were analyzed by compartmental modeling. The effects of lovastatin on VLDL TG metabolism were compared with those previously determined on VLDL apoB metabolism in these subjects. Lovastatin therapy was associated with decreased concentrations of VLDL TG in five of six patients and decreased VLDL apoB concentrations in all six. VLDL TG production rates (PR) decreased in five patients, with the mean for the group decreasing from 14.1 +/- 7.1 to 10.3 +/- 4.0 mg/kg/h (P less than .05). VLDL apoB PR also decreased in five patients, with the mean decreasing from 21.8 +/- 20.3 to 12.2 +/- 9.0 mg/kg/d (P = .11). Changes in VLDL TG concentrations during lovastatin treatment were correlated with changes in VLDL apoB concentrations (r = .74, P = .09) and in VLDL TG PR (r = .91, P = .01). Changes in VLDL TG PR were also related to changes in VLDL apoB PR (r = .62, P = NS). There were no consistent changes in the fractional catabolic rates of either VLDL TG or VLDL apoB during lovastatin therapy.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/1588827/Effects_of_lovastatin_therapy_on_very_low_density_lipoprotein_triglyceride_metabolism_in_subjects_with_combined_hyperlipidemia:_evidence_for_reduced_assembly_and_secretion_of_triglyceride_rich_lipoproteins_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0026-0495(92)90206-P DB - PRIME DP - Unbound Medicine ER -